JP2021530551A5 - - Google Patents

Info

Publication number
JP2021530551A5
JP2021530551A5 JP2021503813A JP2021503813A JP2021530551A5 JP 2021530551 A5 JP2021530551 A5 JP 2021530551A5 JP 2021503813 A JP2021503813 A JP 2021503813A JP 2021503813 A JP2021503813 A JP 2021503813A JP 2021530551 A5 JP2021530551 A5 JP 2021530551A5
Authority
JP
Japan
Prior art keywords
administration
pharmaceutical composition
composition according
agents
excipient
Prior art date
Application number
JP2021503813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530551A (ja
JPWO2020023614A5 (https=
JP7611813B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043202 external-priority patent/WO2020023614A1/en
Publication of JP2021530551A publication Critical patent/JP2021530551A/ja
Publication of JP2021530551A5 publication Critical patent/JP2021530551A5/ja
Publication of JPWO2020023614A5 publication Critical patent/JPWO2020023614A5/ja
Priority to JP2024154560A priority Critical patent/JP2024170583A/ja
Application granted granted Critical
Publication of JP7611813B2 publication Critical patent/JP7611813B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021503813A 2018-07-24 2019-07-24 超高速凍結による表面改質された治療活性粒子の組成物 Active JP7611813B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024154560A JP2024170583A (ja) 2018-07-24 2024-09-09 超高速凍結による表面改質された治療活性粒子の組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702674P 2018-07-24 2018-07-24
US62/702,674 2018-07-24
PCT/US2019/043202 WO2020023614A1 (en) 2018-07-24 2019-07-24 Compositions of surface-modified therapeutically active particles by ultra-rapid freezing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024154560A Division JP2024170583A (ja) 2018-07-24 2024-09-09 超高速凍結による表面改質された治療活性粒子の組成物

Publications (4)

Publication Number Publication Date
JP2021530551A JP2021530551A (ja) 2021-11-11
JP2021530551A5 true JP2021530551A5 (https=) 2022-08-01
JPWO2020023614A5 JPWO2020023614A5 (https=) 2022-08-01
JP7611813B2 JP7611813B2 (ja) 2025-01-10

Family

ID=69181152

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021503813A Active JP7611813B2 (ja) 2018-07-24 2019-07-24 超高速凍結による表面改質された治療活性粒子の組成物
JP2024154560A Pending JP2024170583A (ja) 2018-07-24 2024-09-09 超高速凍結による表面改質された治療活性粒子の組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024154560A Pending JP2024170583A (ja) 2018-07-24 2024-09-09 超高速凍結による表面改質された治療活性粒子の組成物

Country Status (12)

Country Link
US (1) US20210338671A1 (https=)
EP (1) EP3827260A4 (https=)
JP (2) JP7611813B2 (https=)
KR (1) KR20210038583A (https=)
CN (1) CN112673257B (https=)
AU (1) AU2019311086A1 (https=)
BR (1) BR112021001290A2 (https=)
CA (1) CA3106618A1 (https=)
EA (1) EA202190331A1 (https=)
IL (1) IL280342A (https=)
MX (1) MX2021000796A (https=)
WO (1) WO2020023614A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN113398079B (zh) * 2020-03-16 2024-01-19 鲁南制药集团股份有限公司 一种注射用氟达拉滨冻干粉
BR112023001929A2 (pt) 2020-09-03 2023-03-14 Philip Morris Products Sa Composições em pó ativas de baixa higroscopicidade
US20230301919A1 (en) * 2020-09-03 2023-09-28 Philip Morris Products S.A. Freeze dried low hygroscopicity active powder compositions
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CN117241786A (zh) * 2021-03-12 2023-12-15 德克萨斯大学系统董事会 使用基于悬浮液的薄膜冷冻制备干燥粉末的方法
US12015755B2 (en) 2021-03-25 2024-06-18 Korea Advanced Institute Of Science And Technology Real-time omnidirectional stereo matching method using multi-view fisheye lenses and system thereof
CN113484469B (zh) * 2021-06-30 2022-11-18 中国科学院青海盐湖研究所 水合盐体系相变储能材料纳米尺度相分离的原位表征方法
CN116440084A (zh) * 2022-01-07 2023-07-18 浙江萃泽医药科技有限公司 一种可吸入的药物粉末制剂及其制备方法
AU2023366929A1 (en) 2022-10-25 2025-05-08 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08310969A (ja) * 1995-05-22 1996-11-26 Lion Corp 固形薬品組成物及びその製造方法
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CN1750811A (zh) * 2001-10-19 2006-03-22 巴克斯特国际公司 在冷冻水基质中包括颗粒的稳定组合物
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US9061027B2 (en) * 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
WO2007011396A2 (en) * 2004-10-29 2007-01-25 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
US8361439B1 (en) * 2005-01-04 2013-01-29 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
WO2007053923A2 (en) * 2005-11-11 2007-05-18 Biolab Sanus Farmacêutica Ltda. Solid pharmaceutical composition comprising agglomerate nanoparticles and a process for producing the same
WO2011046842A1 (en) * 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US10973763B2 (en) * 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
US9801855B2 (en) * 2012-03-07 2017-10-31 National Institute Of Pharmaceutical Education And Research (Niper) Nanocrystalline solid dispersion compositions and process of preparation thereof
JP6940416B2 (ja) * 2015-05-01 2021-09-29 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 多剤脆性マトリックス組成物

Similar Documents

Publication Publication Date Title
JP2021530551A5 (https=)
Khan et al. An overview of nanostructured lipid carriers and its application in drug delivery through different routes
Chae et al. Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis
Onugwu et al. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases
US9017718B2 (en) Dual and single layer dosage forms
Hooda et al. A review on oral mucosal drug delivery system
Sharma et al. Recent developments in nanoparticles for the treatment of diabetes
JP2000505430A (ja) ニコチンの結腸送達による炎症性腸疾患の治療
RU2751508C2 (ru) Оромукозные нановолоконные носители для терапевтического лечения
JP2024071397A5 (https=)
Lu et al. Distribution of α-asarone in brain following three different routes of administration in rats
JPWO2020023614A5 (https=)
US20180042860A1 (en) Method for producing a pharmaceutical composition of polymeric nanoparticles for treating neuropathic pain caused by peripheral nerve compression
KR20200030064A (ko) 암 및 안 질환의 치료를 위한 알부민 나노입자들
JP2014516045A (ja) 肺に投与するための安定化剤でコーティングされた生体適合性ナノおよびマイクロ粒子
JP2018533579A5 (https=)
US20200222412A1 (en) Methods and compositions for treating pulmonary hypertension
Mirmeera et al. Solid lipid nanoparticles of rebamipide: formulation, characterization and in vivo pharmacokinetic evaluation
AU2022209699A9 (en) Intranasal formulations and delivery of somatostatin mimetics and uses thereof
WO2023087345A1 (zh) 一种用于治疗肺动脉高压的曲前列尼尔气溶胶吸入剂的雾化方法
JP2018534244A5 (https=)
Chang et al. Nasal drug delivery
US20240108573A1 (en) Nanolipid carrier based formulation for brain delivery through intranasal route and its preparation process
Chugh et al. Intranasal drug delivery: a novel approach
Paczkowska-Walendowska et al. Mucoadhesive chitosan-based drug carriers for local application